These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12637728)

  • 1. Cancer. Developing molecular biomarkers for cancer.
    Ransohoff DF
    Science; 2003 Mar; 299(5613):1679-80. PubMed ID: 12637728
    [No Abstract]   [Full Text] [Related]  

  • 2. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.
    Cui H; Cruz-Correa M; Giardiello FM; Hutcheon DF; Kafonek DR; Brandenburg S; Wu Y; He X; Powe NR; Feinberg AP
    Science; 2003 Mar; 299(5613):1753-5. PubMed ID: 12637750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imprinting and colorectal cancer.
    Miyaki M
    Nat Med; 1998 Nov; 4(11):1236-7. PubMed ID: 9809540
    [No Abstract]   [Full Text] [Related]  

  • 4. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability.
    Cui H; Horon IL; Ohlsson R; Hamilton SR; Feinberg AP
    Nat Med; 1998 Nov; 4(11):1276-80. PubMed ID: 9809551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer.
    Oshima T; Akaike M; Yoshihara K; Shiozawa M; Yamamoto N; Sato T; Yamada R; Fujii S; Rino Y; Kunisaki C; Tanaka K; Masuda M; Imada T
    Oncol Rep; 2008 Aug; 20(2):359-64. PubMed ID: 18636198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
    Nosho K; Yamamoto H; Taniguchi H; Adachi Y; Yoshida Y; Arimura Y; Endo T; Hinoda Y; Imai K
    Clin Cancer Res; 2004 Dec; 10(23):7950-7. PubMed ID: 15585629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biology for stage II colorectal cancer: the jury is still out.
    Cascinu S; Zaniboni A; Scartozzi M; Meriggi F
    J Clin Oncol; 2007 Jul; 25(19):2861; author reply 2862-3. PubMed ID: 17602095
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent advances in the molecular diagnosis and prognosis of colorectal cancer.
    Huerta S
    Expert Rev Mol Diagn; 2008 May; 8(3):277-88. PubMed ID: 18598107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The footprints of cancer development: Cancer biomarkers.
    Ullah MF; Aatif M
    Cancer Treat Rev; 2009 May; 35(3):193-200. PubMed ID: 19062197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
    J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of imprinting in IGF2 in colorectal carcinoma assessed by microdissection.
    Maenaka S; Hikichi T; Imai MA; Minamoto T; Kawahara E
    Oncol Rep; 2006 Apr; 15(4):791-5. PubMed ID: 16525660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-II methylation status in lymphocyte DNA and colon cancer risk in the Northern Sweden Health and Disease cohort.
    Kaaks R; Stattin P; Villar S; Poetsch AR; Dossus L; Nieters A; Riboli E; Palmqvist R; Hallmans G; Plass C; Friesen MD
    Cancer Res; 2009 Jul; 69(13):5400-5. PubMed ID: 19549920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation, field effects, and colorectal cancer.
    Giovannucci E; Ogino S
    J Natl Cancer Inst; 2005 Sep; 97(18):1317-9. PubMed ID: 16174847
    [No Abstract]   [Full Text] [Related]  

  • 14. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
    Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
    Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetics: surveillance team against cancer.
    Klein G
    Nature; 2005 Mar; 434(7030):150. PubMed ID: 15758980
    [No Abstract]   [Full Text] [Related]  

  • 16. [Loss of IGF2 imprinting in colorectal cancer].
    Wang Y; Li GW; Wen BG
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):71-3. PubMed ID: 15881352
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular screening testing for colorectal cancer.
    Levin B
    Clin Cancer Res; 2006 Sep; 12(17):5014-7. PubMed ID: 16951215
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of DNA methylation for cancer detection: promises and challenges.
    Zhu J; Yao X
    Int J Biochem Cell Biol; 2009 Jan; 41(1):147-54. PubMed ID: 18834953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Of what value genomics in colorectal cancer? Opportunities and challenges.
    Johnston PG
    J Clin Oncol; 2004 May; 22(9):1538-9. PubMed ID: 15051754
    [No Abstract]   [Full Text] [Related]  

  • 20. Empirical Bayes screening of many p-values with applications to microarray studies.
    Datta S; Datta S
    Bioinformatics; 2005 May; 21(9):1987-94. PubMed ID: 15691856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.